Announcement on Progress in Repurchasing Shares
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/sichuan-biokin-pharmaceutical-co-ltdannouncement-on-progress-in-repurchasing-shares
Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Biokin Pharmaceutical
- Announcement on Resignation of Securities Affairs Representative
- Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer
- Announcement on Voluntary Disclosure of the Approval for Market Launch of Izaberonramab (BL-B01D1/iza-bren)
- Announcement on Voluntary Disclosure of Receiving Drug Clinical Trial Approval Notice for BL-M14D1 for Injection (DLL3 ADC) in Combination Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer
- Announcement on Receipt of the Notice of Registration Acceptance from the National Association of Financial Market Institutional Investors
Later from Sichuan Biokin Pharmaceutical
- Announcement on Implementation Results of Share Repurchase
- Announcement on Voluntary Disclosure of Approval of the Marketing Application for BL-B01D1/iza-bren for Treatment of Esophageal Cancer
- Announcement on Voluntary Disclosure of the Completion of First Subject Enrollment in the Phase III Clinical Trial of BL-B01D1/iza-bren for the Treatment of Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-Based Chemotherapy
- Announcement on the Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren (HER2 ADC) for Injection in Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Failed Platinum-Based Chemotherapy
- Announcement on Voluntary Disclosure of Completing Administration of the First Subject in the Global Multicenter Phase‑III Clinical Trial of BL‑M14D1 (DLL3 ADC) for Injection Combined With Immunotherapy as First‑line Treatment for Extensive‑stage Small Cell Lung Cancer
Follow Sichuan Biokin Pharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Biokin Pharmaceutical